Publications by authors named "David Shames"

Claim this Profile
D
Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 Trials.
Roy S Herbst, Hen Prizant, Daniel Ruderman, Jake Conway, John Shamshoian, David Shames

J Thorac Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.
Tianshi Lu, Habib Hamidi, Mark A Socinski, Martin Reck, Federico Cappuzzo, David S Shames

Nat Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING.
Yoo Sun Kim, Barzin Y Nabet, Briana N Cortez, Nai-Yun Sun, Robin Sebastian, David S Shames

J Clin Invest· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents.
Anne C Chiang, Russell W Madison, Zoe June Assaf, Alexander Fine, Yi Cao, David Shames

JTO Clin Res Rep· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer.
Xueping Qu, Habib Hamidi, Radia M Johnson, Ethan S Sokol, Eva Lin, David Shames

Nat Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of a serum proteomic test for predicting patient outcomes in advanced non-small cell lung cancer treated with atezolizumab or docetaxel.
Minu K Srivastava, Wei Zou, Mark McCleland, Joanna Roder, Senait Asmellash, David S Shames

J Immunother Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer.
Benjamin B Morris, Simon Heeke, Yuanxin Xi, Lixia Diao, Qi Wang, David S Shames

Mol Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T cells.
Xiangnan Guan, Ruozhen Hu, Yoonha Choi, Shyam Srivats, Barzin Y Nabet, David S Shames

Nature· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer.
Benjamin B Morris, Simon Heeke, Yuanxin Xi, Lixia Diao, Qi Wang, David S Shames

bioRxiv· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T cells.
Xiangnan Guan, Ruozhen Hu, Yoonha Choi, Shyam Srivats, Barzin Y Nabet, David S Shames

Nature· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150.
Anika Mang, Wei Zou, Vinzent Rolny, Martin Reck, Daniel Cigoianu, David S Shames

Tumour Biol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.
Barzin Y Nabet, Habib Hamidi, Myung Chang Lee, Romain Banchereau, Stefanie Morris, David S Shames

Cancer Cell· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T cells.
Xiangnan Guan, Ruozhen Hu, Yoonha Choi, Shyam Srivats, Barzin Y Nabet, David S Shames

Nature· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T cells.
Xiangnan Guan, Ruozhen Hu, Yoonha Choi, Shyam Srivats, Barzin Y Nabet, David S Shames

Nature· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analytical evaluation of circulating tumor DNA sequencing assays.
Wenjin Li, Xiayu Huang, Rajesh Patel, Erica Schleifman, Shijing Fu, David S Shames

Sci Rep· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
Jamie E Chaft, Filiz Oezkan, Mark G Kris, Paul A Bunn, Ignacio I Wistuba, David S Shames

Nat Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
Stephen V Liu, Tony S K Mok, Barzin Y Nabet, Aaron S Mansfield, Richard De Boer, David S Shames

Lung Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.
Bruna Pellini, Russell W Madison, Merrida A Childress, Shoshana T Miller, Ole Gjoerup, David S Shames

Clin Cancer Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.
Zoe June F Assaf, Wei Zou, Alexander D Fine, Mark A Socinski, Amanda Young, David S Shames

Nat Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
Jamie E Chaft, Filiz Oezkan, Mark G Kris, Paul A Bunn, Ignacio I Wistuba, David S Shames

Nat Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Solange Peters, Rafal Dziadziuszko, Alessandro Morabito, Enriqueta Felip, Shirish M Gadgeel, David S Shames

Nat Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
Edward S Kim, Vamsidhar Velcheti, Tarek Mekhail, Cindy Yun, Sarah M Shagan, David S Shames

Nat Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer.
Namrata S Patil, Barzin Y Nabet, Sören Müller, Hartmut Koeppen, Wei Zou, David S Shames

Cancer Cell· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in mutated non-small cell lung cancer with , or comutations: subgroup results from the phase III IMpower150 trial.
Howard Jack West, Mark McCleland, Federico Cappuzzo, Martin Reck, Tony Sk Mok, David Shames

J Immunother Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy.
Wei Zou, Stephanie J Yaung, Frederike Fuhlbrück, Marcus Ballinger, Eric Peters, David S Shames

JCO Precis Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis